MiR-15a, miR-16-1 and miR-17-92 cluster expression are linked to poor prognosis in multiple myeloma

Leuk Res. 2012 Dec;36(12):1505-9. doi: 10.1016/j.leukres.2012.08.021. Epub 2012 Sep 7.

Abstract

Multiple myeloma (MM) is characterized by a profound genomic instability of potential prognostic relevance. Loss of chromosome 13, observed in almost half of patients, negatively affects prognosis. MiR-15a, miR16-1 and miR-17-92 cluster, located on 13q, play important roles in the regulation of cell proliferation, differentiation and apoptosis. Therefore, we investigated a possible correlation of miRNA expression with chromosome 13 deletions (del(13)) and prognosis. We measured the expression of miR-15a, miR16-1 in 70 newly diagnosed MM patients and miR-17-92 cluster in 85 newly diagnosed MM patients by quantitative real-time PCR analyses. MiR-15a, miR-16-1 and miR-17-92 cluster expression levels are independent of the del(13). High levels of miR-15a, miR-16-1, miR-17, miR-20a and miR-92-1 are associated with shorter progression-free survival (PFS), suggesting poor prognosis. Our data suggest that the expression of specific miRNAs may be contributing to MM prognosis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Antineoplastic Agents / pharmacology
  • Antineoplastic Agents / therapeutic use
  • Chromosome Deletion*
  • Chromosomes, Human, Pair 13*
  • Disease-Free Survival
  • Female
  • Gene Expression Regulation, Neoplastic
  • Genomic Instability
  • Humans
  • Male
  • MicroRNAs / genetics*
  • Middle Aged
  • Multigene Family
  • Multiple Myeloma / drug therapy
  • Multiple Myeloma / genetics*
  • Multiple Myeloma / mortality
  • Neoplasm Staging
  • RNA, Long Noncoding
  • Real-Time Polymerase Chain Reaction

Substances

  • Antineoplastic Agents
  • MIR17HG, human
  • MIRN15 microRNA, human
  • MIRN16 microRNA, human
  • MicroRNAs
  • RNA, Long Noncoding